Cristhian Emmanuel Scatularo *

Autor invitado por SIIC

Diagnóstico diferencial y tratamiento

ABORDAJE DEL TROMBOEMBOLISMO PULMONAR AGUDO EN TIEMPOS DE SARS-COV-2

La infección por SARS-CoV-2 aumenta el riesgo de presentar tromboembolismo pulmonar agudo debido a la activación de la cascada de coagulación, lo que sugiere un posible beneficio clínico de la anticoagulación en estos pacientes. Asimismo, existen similitudes clínicas entre ambas afecciones, y no son mutuamente excluyentes, por lo que establecer un adecuado diagnóstico diferencial es fundamental.

*Cristhian Emmanuel Scatularo
describe para SIIC los aspectos relevantes de su trabajo
TROMBOEMBOLISMO PULMONAR AGUDO EN TIEMPOS DE SARS-COV-2: DIAGNÓSTICO Y TRATAMIENTO
Institución principal de la investigación
*Sanatorio de la Trinidad - Palermo, Ciudad de Buenos Aires, Argentina
Imprimir nota

Referencias bibliográficas
1. Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 382:1708-1720, 2020.
2. Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention. JAMA 323(13):1239-1242, 2020.
3. Chen T, Wu D, Chen H, et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. BMJ 368:m1091, 2020.
4. Tang N, Li D, Wang X, et al. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost 18(4):844-847, 2020.
5. Wong RS, Wu A, To KF, et al. Haematological manifestations in patients with severe acute respiratory syndrome: retrospective analysis. BM 326(7403):1358-1362, 2003.
6. Klok F, Kruip M, Van der Meer N, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res 2020 Apr 10. [Epub ahead of print]
7. Poissy J, Goutay J, Caplan M, et al. Pulmonary embolism in COVID-19 patients: awareness of an increased prevalence. Circulation 142(2):184-186, 2020.
8. Ullah W, Saeed R, Sarwar U, et al. COVID-19 complicated by acute pulmonary embolism and right-sided heart failure. JACC Case Reports 2(9):1379-1382, 2020.
9. Danzi GB, Loffi M, Galeazzi G, Gherbesi E. Acute pulmonary embolism and COVID-19. Eur Heart J. 2020 Mar 30 [Epub ahead of print]
10. Milbrandt EB, Reade MC, Lee M, et al. Prevalence and significance of coagulation abnormalities in community-acquired pneumonia. Mol Med 15(11-12):438-445, 2009.
11. Carsana L, Sonzogni A, Nasr A, et al. Pulmonary post-mortem findings in a large series of COVID-19 cases from Northern Italy. Lancet Infect Dis 20(10):1135-1140, 2020.
12. Wichmann D, Sperhake J, Lïtgehetmann M, et al. Autopsy findings and venous thromboembolism in patients with COVID-19: a prospective cohort study. Ann Intern Med 2020; [Epub ahead of print 6 May 2020]
13. Digby GC, Kukla P, Zhan ZQ, et al. The value of electrocardiographic abnormalities in the prognosis of pulmonary embolism: a consensus paper. Ann Noninvasive Electrocardiol 20(3):207-223, 2015.
14. Zhou P, Yang XL, Wang XG, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 579(7798):270-273, 2020.
15. Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA 323(11):1061-1069, 2020.
16. Wu C, Chen X, Cai Y, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med 180(7):934-943, 2020.
17. Konstantinides SV, Meyer G, Becattini C, et al. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS): The Task Force for the diagnosis and management of acute pulmonary embolism of the European Society of Cardiology (ESC). Eur Resp J 54(3):1901647, 2019.
18. B?lohlïvek J, Dytrych V, Linhart A. Pulmonary embolism, part I: Epidemiology, risk factors and risk stratification, pathophysiology, clinical presentation, diagnosis and nonthrombotic pulmonary embolism. Exp Clin Cardiol 18(2):129-138, 2013.
19. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395:497-506, 2020.
20. Yang X, Yu Y, Xu J, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med 8(5):475-481, 2020.
21. Gao Y, Li T, Han M, et al. Diagnostic utility of clinical laboratory data determinations for patients with the severe COVID-19. J Med Virol 92(7):791-796, 2020.
22. Lippi G, Salvagno GL, Ippolito L, et al. Shortened activated partial thromboplastin time: causes and management. Blood Coagul Fibrinolysis 21:459-463, 2010.
23. Lippi G, Plebani M, Michael Henry B. Thrombocytopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: A meta-analysis. Clin Chim Acta 506:145-148, 2020.
24. Lippi G, Favaloro EJ. D-dimer is associated with severity of coronavirus disease 2019 (COVID-19): a pooled analysis. Thromb Haemost 120(5):876-878, 2020.
25. Witkowski M, Landmesser U, Rauch U. Tissue factor as a link between inflammation and coagulation. Trends Cardiovasc Med 26(4):297-303, 2016.
26. Mehta P, McAuley DF, Brown M, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet 395(10229):1033-1034, 2020.
27. Zhang C, Shi L, Wang FS. Liver injury in COVID-19: management and challenges. Lancet Gastroenterol Hepatol 5(5):428-430, 2020.
28. Zhang Y, Xiao M, Zhang S, et al. Coagulopathy and antiphospholipid antibodies in patients with Covid-19. N Engl J Med 382(17):e38, 2020.
29. Léonard-Lorant I, Delabranche X, Séverac F, et al. Acute pulmonary embolism in COVID-19 patients on CT angiography and relationship to D-dimer levels. Radiolog 296(3):E189-E191, 2020.
30. Kearon C, de Wit K, Parpia S, et al.; Investigators PES. Diagnosis of pulmonary embolism with D-dimer. N Engl J Med 381(22):2125-2134, 2019.
31. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 395:1054-1062, 2020.
32. Libby P, Simon DI. Inflammation and thrombosis: the clot thickens. Circulation 103:1718-1720, 2001.
33. Abul Y, Karakurt S, Ozben B, et al. C-reactive protein in acute pulmonary embolism. J Investig Med 59(1):8-14, 2011.
34. Bikdeli B, Madhavan MV, Jimenez D, et al. COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up. J Am Coll Cardiol 75(23):2950-2973, 2020.
35. Choi AD, Abbara S, Branch KR, et al. Society of Cardiovascular Computed Tomography Guidance for Use of Cardiac Computed Tomography Amidst the COVID-19 Pandemic. J Cardiovasc Comput Tomogr 2020 Mar 21 [Epub ahead of print]
36. Liu P, Tan X. Emerging 2019 novel coronavirus (2019-nCoV) pneumonia. Radiology 8:200257, 2020.
37. Zuckier LS, Moadel R, Haramati L, Freeman L. Diagnostic Evaluation of Pulmonary Embolism During the COVID-19 Pandemic. J Nucl Med 61(5):630-631, 2020.
38. Jacobi A, Chung M, Bernheim, A, Eber C. Portable chest X-ray in coronavirus disease-19 (COVID-19): a pictorial review. Clinical Imaging 64:35-42, 2020.
39. Moore AJE, Wachsmann, J, Chamarthy, MR, et al. Imaging of acute pulmonary embolism: an update. Cardiovasc Diagn Ther 8(3):225-243, 2018.
40. Lippi G, Lavie CJ, Sanchis-Gomar F. Cardiac troponin I in patients with coronavirus disease 2019 (COVID-19): Evidence from a meta-analysis. Prog Cardiovasc Dis 63(3):390-391, 2020.
41. Januzzi JL. Troponin and BNP use in COVID-19. Cardiology Magazine: American College of Cardiology, 2020.
42. Thygesen K, Alpert JS, Jaffe AS, et al. Fourth universal definition of myocardial infarction 2018. J Am Coll Cardiol 72:2231-2264, 2018.
43. Kirkpatrick JN, Grimm R, Johri AM, et al. Recommendations for echocardiography laboratories participating in cardiac Point of Care Cardiac Ultrasound (POCUS) and Critical Care Echocardiography Training: report from the American Society of Echocardiography. J Am Soc Echocardiogr 33(4):409-422, 2020.
44. Kumar P, Gordon LA, Brooks KM, et al. Differential influence of the antiretroviral pharmacokinetic enhancers ritonavir and cobicistat on intestinal P-glycoprotein transport and the pharmacokinetic/pharmacodynamic disposition of dabigatran. Antimicrob Agents Chemother 61(11):e01201-01217, 2017.
45. Stïllberger C, Finsterer J. Relevance of P-glycoprotein in stroke prevention with dabigatran, rivaroxaban, and apixaban. Herz 40(Suppl 2):140-145, 2015.
46. Egan G, Hughes CA, Ackman ML. Drug interactions between antiplatelet or novel oral anticoagulant medications and antiretroviral medications. Ann Pharmacother 48(6):734-740, 2014.
47. Steffel J, Verhamme P, Potpara TS, et al.; ESC Scientific Document Group. The 2018 EHRA Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J 39(16):1330-1393, 2018.
48. Lew TW, Kwek TK, Tai D, et al. Acute respiratory distress syndrome in critically ill patients with severe acute respiratory syndrome. JAMA 290:374-380, 2003.
49. Kucher N, Goldhaber SZ. Managemenet of massive pulmonary embolism. Circulation 112(2):e28-32, 2005.
50. Ain DL, Albaghdadi M, Giri J, et al. Extra-corporeal membrane oxygenation and outcomes in massive pulmonary embolism: Two eras at an urban tertiary care hospital. Vasc Med 23:60-64, 2018.
51. De Winter MA, Vlachojannis GJ, Ruigrok D, et al. Rationale for catheter-based therapies in acute pulmonary embolism. Eur Heart J 21(I):I16-I22, 2019.
52. Giri J, Sista AK, Weinberg I, et al. Interventional therapies for acute pulmonary embolism: current status and principles for the development of novel evidence: a Scientific Statement from the AHA. Circulation 140:e774-e801, 2019.
53. Chatterjee S, Chakraborty A, Weinberg I, et al. Thrombolysis for pulmonary embolism and risk of all-cause mortality, major bleeding, and intracranial hemorrhage: a metaanalysis. JAMA 311:2414-2421, 2014.
54. Jimenez D, Bikdeli B, Marshall PS, Tapson V. Aggressive treatment of intermediate-risk patients with acute symptomatic pulmonary embolism. Clin Chest Med 39:569-581, 2018.
55. Jaff MR, McMurtry MS, Archer SL, et al. Management of massive and submassive pulmonary embolism, iliofemoral deep vein thrombosis, and chronic thromboembolic pulmonary hypertension: a scientific statement from the AHA. Circulation 123:1788-830, 2011.
56. Romaguera R, Cruz-Gonzalez I, Ojeda S, et al. Gestión de salas de procedimientos invasivos cardiológicos durante el brote de coronavirus COVID-19. Documento de consenso de la Asociación de Cardiología Intervencionista y la Asociación del Ritmo Cardíaco de la SEC. REC Interv Cardiol 2:106-111, 2020.
57. Welt Frederick GP, Shah PB, Aronow HD, et al. Catheterization laboratory considerations during the coronavirus (COVID-19) pandemic: from ACC Interventional Council and SCAI. J Am Coll Cardiol 75:2372-2375, 2020.
58. Wood DA, Sathananthan J, Gin K, et al. Precautions and procedures for coronary and structural cardiac interventions during the COVID-19 pandemic: Guidance from Canadian Association of Interventional Cardiology. Can J Cardiol 36(5):780-783, 2020.
59. Kolkailah AA, Hirji S Piazza, Ejiofor JI, et al. Surgical pulmonary embolectomy and catheter-directed thrombolysis for treatment of submassive pulmonary embolism. J Card Surg 33(5):252-259, 2018.
60. Bikdeli B, Chatterjee S, Desai NR, et al. Inferior vena cava filters to prevent pulmonary embolism: systematic review and meta-analysis. J Am Coll Cardiol 70:1587-1597, 2017.
61. Hollander JE, Carr BG. Virtually perfect?: Telemedicine for Covid-19. N Engl J Med 382:1679-1681, 2020.
62. Boukhris M, Hillani A, Moroni F, et al. Cardiovascular implications of the COVID-19 pandemic: a global perspective. Can J Cardiol 36(7):1068-1080, 2020.
63. Helmes J, Tacquard C, Severac F, et al. High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study. Intensive Care Med 46(6):1089-1098, 2020.
64. Lodigiani C, Iapichino G, Carenzo L, et al. Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Milan, Italy. Thromb Res 191:9-14, 2020.
65. Ciceri F, Beretta L, Scandroglio AM, et al. Microvascular COVID-19 lung vessels obstructive thromboinflammatory syndrome (MicroCLOTS): an atypical acute respiratory distress syndrome working hypothesis. Crit Care Resusc 22(2):95-97, 2020.
66. McGonagle D, O'Donnell J, Sharif K, et al. Immune mechanisms of pulmonary intravascular coagulopathy in COVID-19 pneumonia. Lancet Rheumatol 2(7):e437-e445, 2020.
67. Tang N, Bai H, Chen X, et al. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost 18(5):1094-1099, 2020.
68. Paranjpe I, Fuster V, Lala A, et al. Association of treatment dose anticoagulation with in-hospital survival among hospitalized patients with COVID-19. J Am Coll Cardiol 76(1):122-124, 2020.